Daclatasvir, sold under the brand name Daklinza, is an antiviral medication used in combination with other drugs to treat hepatitis C virus (HCV) infections. It is a NS5A inhibitor that works by interfering with viral replication and assembly. Daclatasvir is typically prescribed with sofosbuvir, ribavirin, or peginterferon, depending on the HCV genotype and the presence of liver cirrhosis. It is taken orally once daily and is known for its high cure rates and shorter treatment duration compared to older hepatitis C treatments.

Parent: Daclatasvir
Impurities in Daclatasvir can arise due to chemical synthesis, degradation, or improper storage conditions. Regulatory agencies such as the FDA, EMA, and ICH enforce impurity limits to ensure drug safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Common side effects include: